Cargando…
Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear
BACKGROUND: Hyperconsolidation of aversive associations and poor extinction learning have been hypothesized to be crucial in the acquisition of pathological fear. Previous animal and human research points to the potential role of the catecholaminergic system, particularly noradrenaline and dopamine,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515133/ https://www.ncbi.nlm.nih.gov/pubmed/35748393 http://dx.doi.org/10.1093/ijnp/pyac038 |
_version_ | 1784798424481136640 |
---|---|
author | Sperl, Matthias F J Panitz, Christian Skoluda, Nadine Nater, Urs M Pizzagalli, Diego A Hermann, Christiane Mueller, Erik M |
author_facet | Sperl, Matthias F J Panitz, Christian Skoluda, Nadine Nater, Urs M Pizzagalli, Diego A Hermann, Christiane Mueller, Erik M |
author_sort | Sperl, Matthias F J |
collection | PubMed |
description | BACKGROUND: Hyperconsolidation of aversive associations and poor extinction learning have been hypothesized to be crucial in the acquisition of pathological fear. Previous animal and human research points to the potential role of the catecholaminergic system, particularly noradrenaline and dopamine, in acquiring emotional memories. Here, we investigated in a between-participants design with 3 groups whether the noradrenergic alpha-2 adrenoreceptor antagonist yohimbine and the dopaminergic D2-receptor antagonist sulpiride modulate long-term fear conditioning and extinction in humans. METHODS: Fifty-five healthy male students were recruited. The final sample consisted of n = 51 participants who were explicitly aware of the contingencies between conditioned stimuli (CS) and unconditioned stimuli after fear acquisition. The participants were then randomly assigned to 1 of the 3 groups and received either yohimbine (10 mg, n = 17), sulpiride (200 mg, n = 16), or placebo (n = 18) between fear acquisition and extinction. Recall of conditioned (non-extinguished CS+ vs CS−) and extinguished fear (extinguished CS+ vs CS−) was assessed 1 day later, and a 64-channel electroencephalogram was recorded. RESULTS: The yohimbine group showed increased salivary alpha-amylase activity, confirming a successful manipulation of central noradrenergic release. Elevated fear-conditioned bradycardia and larger differential amplitudes of the N170 and late positive potential components in the event-related brain potential indicated that yohimbine treatment (compared with a placebo and sulpiride) enhanced fear recall during day 2. CONCLUSIONS: These results suggest that yohimbine potentiates cardiac and central electrophysiological signatures of fear memory consolidation. They thereby elucidate the key role of noradrenaline in strengthening the consolidation of conditioned fear associations, which may be a key mechanism in the etiology of fear-related disorders. |
format | Online Article Text |
id | pubmed-9515133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95151332022-09-28 Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear Sperl, Matthias F J Panitz, Christian Skoluda, Nadine Nater, Urs M Pizzagalli, Diego A Hermann, Christiane Mueller, Erik M Int J Neuropsychopharmacol Regular Research Articles BACKGROUND: Hyperconsolidation of aversive associations and poor extinction learning have been hypothesized to be crucial in the acquisition of pathological fear. Previous animal and human research points to the potential role of the catecholaminergic system, particularly noradrenaline and dopamine, in acquiring emotional memories. Here, we investigated in a between-participants design with 3 groups whether the noradrenergic alpha-2 adrenoreceptor antagonist yohimbine and the dopaminergic D2-receptor antagonist sulpiride modulate long-term fear conditioning and extinction in humans. METHODS: Fifty-five healthy male students were recruited. The final sample consisted of n = 51 participants who were explicitly aware of the contingencies between conditioned stimuli (CS) and unconditioned stimuli after fear acquisition. The participants were then randomly assigned to 1 of the 3 groups and received either yohimbine (10 mg, n = 17), sulpiride (200 mg, n = 16), or placebo (n = 18) between fear acquisition and extinction. Recall of conditioned (non-extinguished CS+ vs CS−) and extinguished fear (extinguished CS+ vs CS−) was assessed 1 day later, and a 64-channel electroencephalogram was recorded. RESULTS: The yohimbine group showed increased salivary alpha-amylase activity, confirming a successful manipulation of central noradrenergic release. Elevated fear-conditioned bradycardia and larger differential amplitudes of the N170 and late positive potential components in the event-related brain potential indicated that yohimbine treatment (compared with a placebo and sulpiride) enhanced fear recall during day 2. CONCLUSIONS: These results suggest that yohimbine potentiates cardiac and central electrophysiological signatures of fear memory consolidation. They thereby elucidate the key role of noradrenaline in strengthening the consolidation of conditioned fear associations, which may be a key mechanism in the etiology of fear-related disorders. Oxford University Press 2022-06-24 /pmc/articles/PMC9515133/ /pubmed/35748393 http://dx.doi.org/10.1093/ijnp/pyac038 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of CINP. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Regular Research Articles Sperl, Matthias F J Panitz, Christian Skoluda, Nadine Nater, Urs M Pizzagalli, Diego A Hermann, Christiane Mueller, Erik M Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear |
title | Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear |
title_full | Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear |
title_fullStr | Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear |
title_full_unstemmed | Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear |
title_short | Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear |
title_sort | alpha-2 adrenoreceptor antagonist yohimbine potentiates consolidation of conditioned fear |
topic | Regular Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515133/ https://www.ncbi.nlm.nih.gov/pubmed/35748393 http://dx.doi.org/10.1093/ijnp/pyac038 |
work_keys_str_mv | AT sperlmatthiasfj alpha2adrenoreceptorantagonistyohimbinepotentiatesconsolidationofconditionedfear AT panitzchristian alpha2adrenoreceptorantagonistyohimbinepotentiatesconsolidationofconditionedfear AT skoludanadine alpha2adrenoreceptorantagonistyohimbinepotentiatesconsolidationofconditionedfear AT naterursm alpha2adrenoreceptorantagonistyohimbinepotentiatesconsolidationofconditionedfear AT pizzagallidiegoa alpha2adrenoreceptorantagonistyohimbinepotentiatesconsolidationofconditionedfear AT hermannchristiane alpha2adrenoreceptorantagonistyohimbinepotentiatesconsolidationofconditionedfear AT muellererikm alpha2adrenoreceptorantagonistyohimbinepotentiatesconsolidationofconditionedfear |